Stock Analysis
Karyopharm Therapeutics Inc. (KPTI) Stock Analysis
Karyopharm Therapeutics Inc. (KPTI) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Karyopharm Therapeutics Inc. (KPTI) currently has an AIQ Score of 62/100, indicating a neutral setup. Quality is the strongest factor at 100/100. Momentum is the weakest current factor at 29/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
KPTI at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $0.55 |
| AIQ Score | 62/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Sell |
| Market Cap | $41.93M |
| P/E Ratio (TTM) | -0.08 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | -$2.32 |
| Revenue (quarter ended 2026-06-30) | $33.43M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.95 |
| Volume | 7.49M |
| 52-week range | $0.31-$10.99 |
| RSI 14 | 34.32 |
| 50-Day SMA | $1.38 |
| 200-Day SMA | $6.26 |
| Analyst Price Target | $10.20 |
| Next Earnings | Nov 2, 2026 |
KPTIKaryopharm Therapeutics Inc.
Healthcare / Biotechnology
Relative Leader / Watch
Strong Relative Position
Latest quote
- Momentum29
- Value65
- Quality100
- Risk resilience32
- Sentiment—
KPTI Stock Analysis Summary
Karyopharm Therapeutics Inc. (KPTI) currently has an AIQ Score of 62/100, indicating a neutral setup. Quality is the strongest factor at 100/100. Momentum is the weakest current factor at 29/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, KPTI has AIQ Score of 62/100 with Quality base of 100/100 and fading Momentum at 29/100. Wait for component alignment before adding exposure.
Quality (100/100) leads while Momentum (29/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 28.68% stock move · KPTI classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is KPTI Bullish or Bearish Right Now?
KPTI currently has a neutral overall setup. Quality is the strongest factor at 100/100, while Momentum is weakest at 29/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 100/100.
- - Analyst target implies +1767.79% upside from the latest quote.
- - Momentum is weak at 29/100.
- - Risk Resilience is weak at 32/100.
- - Price is -91.27% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (28 vs 11).
Current Consensus
KPTI's Technical Analysis Consensus is currently Sell, with 11 buy, 6 neutral, and 28 sell votes. KPTI's 14-day RSI is 34.32, which places the stock in a weaker momentum range. KPTI's beta is 0.95, indicating market sensitivity broadly in line with the market.
What Changed in KPTI?
The largest recent change in KPTI is Momentum moving up by 4.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the KPTI Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
KPTI Decision Framework
Public evidence layers, setup checks, and risk context for Karyopharm Therapeutics Inc..
Karyopharm Therapeutics Inc. (KPTI) Stock Analysis
Karyopharm Therapeutics Inc. has an AIQ Score of 62/100 in a Neutral regime. Quality is strongest at 100/100. Beta is 1.04, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | KPTI is in a Neutral AIQ regime with score 62/100. |
| Signal Conflict | The primary conflict is that quality leads at 100/100 while momentum lags at 29/100. |
| Factor Evidence | Momentum 29/100 · Value 65/100 · Quality 100/100 · Risk 32/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 100/100.
Momentum is 29/100 and RSI (14) is 34.3.
KPTI is in a Neutral regime at 62/100.
Risk factor is 32/100 with beta 1.04 and annual volatility 128.22%.
Current conflict: quality leads at 100/100 while momentum lags at 29/100.
KPTI Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
KPTI Fundamentals
KPTI valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
KPTI Technical Analysis
KPTI technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
KPTI Stock Catalysts
Track KPTI earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
KPTI Dividend Analysis
KPTI dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
KPTI Financial Data
KPTI revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
KPTI Risk Analysis
KPTI volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
KPTI Stock News
KPTI stock news, market tone, recent headlines, and catalyst context.
KPTI vs Gene Editing / Genomics / Biotech Peers
Current peer cohort: KPTI · LEGN · MRVI · NTLA · NUVB. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| KPTI Current stock | 62/100 | 65/100 | 29/100 | 32/100 | -1.06 | 128.22% | Current |
| LEGN Legend Biotech | 50/100 | 54/100 | 44/100 | 45/100 | -0.44 | 75.14% | KPTI vs LEGN |
| MRVI Maravai LifeSciences | 38/100 | 34/100 | 42/100 | 46/100 | 1.35 | 68.89% | KPTI vs MRVI |
| NTLA Intellia Therapeutics | 33/100 | 34/100 | 33/100 | 42/100 | -0.5 | 91.78% | KPTI vs NTLA |
| NUVB Nuvation Bio | 38/100 | 34/100 | 31/100 | 43/100 | 0.48 | 83.42% | KPTI vs NUVB |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 22, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts4 recent quarterly periods are available for review.
Checked Oct 23, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching KPTI
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for KPTI
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
KPTI Stock FAQ
What is KPTI stock price today?
Karyopharm Therapeutics Inc.'s current stock price is $0.55. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is KPTI bullish or bearish right now?
KPTI's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is KPTI's market cap?
KPTI's market cap is $41.93M based on the latest completed market-close snapshot from Oct 22, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is KPTI's current P/E ratio?
KPTI's current P/E ratio is -0.08 based on the latest completed market-close snapshot from Oct 22, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is KPTI's RSI?
KPTI's 14-day RSI is 34.32 based on the latest completed market-close snapshot from Oct 22, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is KPTI above its 50-day and 200-day moving averages?
KPTI is -60.32% from its 50-day SMA and -91.27% from its 200-day SMA based on the latest completed market-close snapshot from Oct 22, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is KPTI's next earnings date?
KPTI's next earnings date is currently listed as Nov 2, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does KPTI pay a dividend?
KPTI's dividend yield is 0.00% based on the latest completed market-close snapshot from Oct 22, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.